Articles tagged with Liver Tumors
Researchers at North Carolina State University have developed a mathematical model for computing radiation therapy treatments that could substantially reduce patient side effects while delivering the same results as conventional radiation therapy. The new approach, known as spatiotemporal fractionation, delivers different doses to part...
A new study confirms presence of Fusobacterium in liver metastases of colon cancer patients, correlating with tumor growth and colonization. The bacteria travels with metastatic tumor cells to distant organs, potentially aiding their colonization.
A new study identifies a chimeric gene as the driver of fibrolamellar hepatocellular carcinoma (FL-HCC), a rare and usually lethal liver cancer. The research offers prime targets for drugs to treat the disease, including kinases and cellular signaling systems. Researchers are now working to design therapeutics targeting these pathways.
Researchers discovered a synthetic double-stranded RNA that boosts anti-tumor innate immune functions, potentially preventing liver cancer. The study found that administering the RNA at different stages suppressed tumor formation in mouse models.
Researchers have successfully created mini biological models of human primary liver cancers, known as organoids, in the lab. These tiny laboratory models were used to identify a new drug that could potentially treat certain types of liver cancer, showing promising results for personalized medicine and reducing animal usage.
Researchers at the University of California San Diego School of Medicine found that chronic liver inflammation suppresses immunosurveillance, allowing cancer cells to grow. Inhibiting PD-L1 restored immune function and cleared tumors in mice with NASH-associated mutations.
A USC research team has identified a potential therapeutic target for liver cancer treatment: mitophagy, the removal of damaged mitochondria. This process can cause tumors to proliferate, but temporarily halting it may reduce cancer stem cell growth, leading to tumor regression.
Researchers have developed a new diagnostic method for early detection of hepatocellular carcinoma, based on a simple blood sample containing circulating tumor DNA. The test has been shown to highly correlate with tumor burden, treatment response, and stage of cancer.
Research at Sanford Burnham Prebys Medical Discovery Institute suggests that eliminating p62 protein in surrounding stromal tissue can disrupt tumor supply lines. This could lead to new strategies to target non-oncogenic addictions and undermine cancer growth.
EPFL scientists have discovered metabolic differences between hepatoblastoma subtypes and identified biomarkers to aid in more accurate subtyping. The study reveals that embryonal hepatoblastoma cells use glucose and are sensitive to its metabolism, offering a new approach for personalized treatment.
Researchers at Children's Hospital Los Angeles have successfully defined a rare pediatric malignant liver disease, HEMNOS, which showed positive treatment outcomes when treated like hepatoblastoma. The study found that all patients survived and achieved remission despite being considered high risk.
Researchers at Vanderbilt University developed a novel gene therapy delivery system that uses a human protein called albumin to target cancer cells. The approach overcomes common barriers to successful gene therapy, including drug resistance and toxicity.
A new software technology helps surgeons precisely locate liver tumors during surgery by correcting for the organ's deformation. This innovation has shown to improve registration in over 70% of cases, aiding in more accurate and safer surgical procedures.
Researchers developed a personalized peptide-receptor radionuclide therapy (PRRT) approach, which increased the radiation dose to tumors by up to three times. The treatment showed reduced side effects and improved safety profiles without compromising therapeutic benefits.
Primary colorectal tumors secrete VEGF-A, inducing CXCL1 and CXCR2-positive myeloid-derived suppressor cells to recruit at distant sites, establishing niches for future metastases. Liver-infiltrating MDSCs facilitate tumor cell survival in the new location.
Research identifies PPARγ as a critical regulator of metabolism-associated genes in the liver. Inhibition of PPARγ suppresses tumor growth and reduces tumorigenesis in mouse models.
Researchers have developed a new test that can detect ovarian cancer months earlier than current methods, potentially improving five-year survival rates. The test uses synthetic biomarkers that interact with tumor proteins to release fragments in urine samples.
The TGF-beta cytokine modulates hepatocellular carcinoma cell migration and tumor initiator capacity. The study reveals a dual role of TGF-beta in cancer, acting as both a suppressor and enhancer.
Researchers at the University of Illinois Chicago report that increasing expression of cytokine LIGHT in mice with colon cancer activates the immune system's natural cancer-killing T-cells. This leads to a significant decrease in tumor burden, including primary tumors and metastatic tumors in the liver.
A new study reveals that RAF1 acts as a negative regulator of hepatocellular carcinoma, while promoting growth in inflammatory cells. This finding highlights the need for a more thorough understanding of the disease at the molecular level to design novel therapies.
A recent study discovered that liver cancer drugs fail because the body lacks a balance between two enzymes, Shp2 and Pten. This imbalance activates molecules involved in lipid metabolism, inflammation, and fibrosis, leading to liver disease and cancer.
Researchers at Penn Medicine have developed a fluorescent dye technique that makes tumors glow brightly during surgery, enabling surgeons to distinguish between healthy and cancerous tissue. The tool has shown promise in patients with brain cancer, demonstrating the ability to identify tumor margins and reduce recurrence rates.
Researchers found that cancer tumors interfere with the liver's ability to cope with wasting and impair its response to immunotherapy. Massive caloric supplementation does not vanquish wasting, and immune therapy does not impair the tumor's ability to thrive.
Researchers developed a novel imaging probe that can detect hypoxic tumors with high specificity and sensitivity. The probe uses bioluminescence resonance energy transfer to generate NIR light only in HIF-active hypoxic cells, reducing off-target signals and increasing tumor-to-normal tissue ratio.
A study found Neu5Gc in pig organs, particularly heart, spleen, kidney, and lungs, with concentrations increasing as organs are cooked. This non-human sialic acid sugar molecule may trigger an immune response, leading to chronic inflammation and increased risks of tumor formation and inflammatory diseases.
A MGH team found that treating metastatic colorectal cancer with antiangiogenic drugs increases extracellular matrix components and stiffness, contributing to treatment resistance. Antiangiogenic therapy also attracts suppressor immune cells, reducing the immune response against tumors.
Researchers are investigating the role of SLC13A3, a likely tumor suppressor gene, in kidney cancer. They hope to understand why its expression is suppressed in African American patients and explore its potential as a therapeutic target.
Scientists from TUM discovered that pancreatic cancer cells create a 'niche' in the liver to grow and spread at an exceptionally early stage. This is facilitated by the protein TIMP1, which interacts with hepatic stellate cells to activate them and initiate metastasis.
Researchers discovered that oral microbes like fusobacteria travel through the bloodstream to reach colorectal tumors, where they proliferate and accelerate cancer. The study sheds light on how these bacteria home in on tumors using a protein called Fap2.
Researchers found that circulating tumor DNA is smaller than healthy DNA in cancer patients, allowing for more accurate detection through a simple blood draw. This advancement could enable earlier detection of solid tumors, potentially saving lives.
Dr. Muhammad Asif Qureshi will focus on immunotherapy to slow down or reverse cancers, particularly liver cancer, which is the fifth most common type of cancer in men and ninth in women. The research aims to develop new diagnostics and therapeutics to target the immune system.
Two patients with liver metastasis from melanoma survived for at least 8.5 and 12 years after receiving patient-specific immunotherapeutic vaccines. The vaccines were derived from the patients' own dendritic cells loaded with proteins isolated from their tumors. Co-Editor-in-Chief Donald J. Buchsbaum, PhD, describes these results as
A study at the University of Texas M. D. Anderson Cancer Center found that normal liver cells metabolize dietary fructose differently than cancerous cells, revealing a potential diagnostic marker for liver cancer. The researchers discovered a gene called KHK that is expressed differently in healthy and tumor tissues.
Researchers found that cancer cells can regulate the body's lipid metabolism to increase production of lipids. Minimizing liver production of LDL can deprive tumors of their constant supply and reduce growth. The study aims to test existing medications for hypercholesterolemia on patients undergoing cancer treatment.
The Helmholtz Zentrum Munchen has been awarded 14 ERC grants, with three scientists receiving 6 million euros. Dr. Daniel Razansky is investigating non-invasive brain imaging methods, while Dr. Irmela Jeremias focuses on targeted tumor treatment and Dr. Mathias Heikenwaelder explores immune system interactions in liver disease.
A study found that even small tumors contain extremely high genetic diversity, which can lead to resistance against standard cancer treatments. This raises important questions about how to reevaluate treatment strategies for tumors with high intra-tumor diversity.
Mathematicians at Duke University develop a method to compare common tumor growth models using only two time-point measurements of tumor size. The results suggest breast and liver tumors grow exponentially, while neurological tumors follow the two-thirds power law.
Research suggests that retroviral long-terminal-repeat promoters may contribute to the emergence of hepatocellular carcinoma. The study found that these elements are highly activated in liver cancer tumors and non-tumor tissue from patients with different etiologies, including viral hepatitis or alcohol use.
Researchers discovered a method to reprogram fibroblasts, healthy tissue around tumors, to trap and contain cancer cells. This approach reduces the movement of cancer cells away from the tumor, showing promise in preventing tumor spread. The study has potential for various cancer types and could lead to better ways to control the disease.
A new study has found that detecting small fragments of tumor DNA in a patient's pre-surgery serum samples can predict early recurrence of hepatocellular carcinoma and guide treatment. This non-invasive method may lead to improved survival rates for liver cancer patients.
Researchers at Case Western Reserve University have developed a magnetic resonance imaging (MRI) contrast agent that can detect small aggressive breast cancer tumors and micrometastases. The agent binds to molecular markers expressed in high-risk primary tumors and metastases, generating increased image contrast.
Surgeons report positive outcomes in robotic IVC thrombectomy for renal cancer patients with Level III thrombus. Eight out of nine patients show no evidence of disease after follow-up, with significant advancements in operating room times and blood loss.
Researchers have created a genetically engineered pig model that allows them to induce the development of human-like tumors, reflecting gene pathways and mutations most often observed in human cancer. The 'oncopig' model holds great promise for early detection and treatment of cancers such as pancreatic, liver, lung, and bladder cancers.
The SIRFLOX randomized controlled study found that adding liver-directed SIR-Spheres Y-90 resin microspheres to first-line chemotherapy improved liver tumour control and reduced progression risk. The regimen provided a 7.9-month treatment benefit, translating to a 31% reduction in tumour progression risk.
Researchers at MIT and UCSD developed a new approach to detecting liver tumors using engineered probiotics. The bacteria produce a luminescent signal that can be detected with a common laboratory test, showing high sensitivity in detecting liver tumors larger than one cubic millimeter.
Researchers have developed a model that allows for precise targeting of tumors while reducing dose to surrounding tissues. The rescanning technique compensates for tumor motion, averaging out the delivered dose while keeping doses to normal tissues low.
A novel, non-invasive treatment strategy for Cushing Disease has been discovered using silibinin from milk thistle seeds. The active compound binds to heat shock protein 90, allowing glucocorticoid receptor molecules to dissolve and restore normal ACTH production.
Scientists from the University of Manchester discovered that ATF2 protein suppresses tumour growth in liver cancer models. The study suggests that ATF2's tumor-suppressing function may be more widespread than previously thought.
A new statistical model developed by WPI's Patrick Flaherty allows better identification of different cell types found in solid tumors, enabling more targeted treatment options. The GLAD model accurately predicted the fractions of various subtypes in glioblastoma tumors and has potential applications in breast cancer treatment.
Researchers at University of California, San Diego School of Medicine found that triclosan causes liver fibrosis and cancer in laboratory mice through molecular mechanisms relevant in humans. Long-term exposure to the chemical may lead to liver toxicity, particularly when combined with other compounds.
A recent study published in the British Journal of Surgery found that extending surgical resection after two cycles of chemotherapy may be beneficial for some pediatric patients with hepatoblastoma. The research, conducted at Children's Hospital Los Angeles, suggests a potential reduction in complications from chemotherapy.
Researchers identified CD44 as a potential marker to select patients unresponsive to Sorafenib, a common liver cancer treatment. Patients with a less differentiated mesenchymal phenotype expressing CD44 tend to resist Sorafenib's action, highlighting the need for alternative therapies.
Researchers from CNIO have identified a new marker for cancer stem cells using riboflavin, a pigment that emits green fluorescence. This discovery enables the tracking of cancer stem cells in tumors, which are responsible for chemical resistance and tumor growth.
Researchers have developed dynamic nanoparticles that can be used as contrast agents for MRI and PET scans, deliver chemotherapy directly to tumors, and respond to light to destroy tumor cells. The particles are biocompatible, non-toxic, and can be easily made, making them a promising tool in cancer treatment.
Researchers have shown that injecting a weakened version of the anaerobic bacteria Clostridium novyi can shrink tumors in rats, dogs, and a human patient. The bacteria excise tumor tissue in a precise, localized way that spares surrounding normal tissue.
Cancer cells that break away from tumors can prefer soft environments for growth and proliferation, researchers at the University of Illinois found. The study suggests that this preference may explain why soft tissues are more vulnerable to cancer metastasis and recurrence.
A study by Mayo Clinic researchers found that the size of tumors before treatment is a strong predictor of response to immunotherapy drug MK-3475. The findings suggest that decreasing baseline tumor size through surgery or other means may be more effective in inducing long-lasting remissions.
A University of Colorado Cancer Center study identifies AGL as a key driver of bladder cancer growth, linked to hereditary liver disease glycogen storage disease 3. Low AGL levels correlate with poorer prognosis and increased tumor proliferation.
Researchers at Johns Hopkins Medicine have developed a new technology that uses 3D MRI scans to precisely measure living and dying tumor tissue, allowing for more accurate predictions of patient survival after chemotherapy. The technology has been shown to improve survival rates by up to 19 months in patients with liver tumors.
A new treatment option for metastatic breast cancer patients with liver metastases shows promise in slowing disease progression and improving quality of life. Yttrium-90 radioembolization was safe and provided disease stabilization in 98.5% of treated liver tumors, with many experiencing significant tumor shrinkage.